Global ELISA Analyzer Market Size

Statistics for the 2023 & 2024 Global ELISA Analyzer market size, created by Mordor Intelligence™ Industry Reports. Global ELISA Analyzer size report includes a market forecast to 2029 and historical overview. Get a sample of this industry size analysis as a free report PDF download.

Market Size of Global ELISA Analyzer Industry

ELISA Analyzers Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 2.30 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration High

Major Players

ELISA Analyzers Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

ELISA Analyzer Market Analysis

The ELISA analyzer market is expected to register a CAGR of 2.3% over the forecast period, 2022-2027.

COVID-19 has had both positive and negative impacts on the market studied. For instance, the demand for ELISA analyzers for COVID-19 testing increased during the pandemic. The rise in demand for ELISA testing in the detection of COVID-19 fueled the growth of the market in the later phase of the pandemic. In addition, various in vitro diagnostic companies launched ELISA test kits for the detection of COVID-19 which required the use of ELISA analyzers. For instance, in August 2021, Zeus Scientific Inc received FDA authorization to use the Dynex Agility, Dynex DSX, or Dynex DS2 Automated ELISA Systems to run the ZEUS ELISA SARS-SoV-2 total antibody test system. Hence, this led to a surge in demand for ELISA analyzers during the pandemic.

However, the ELISA analyzer market also experienced a negative impact during the COVID-19 pandemic as the volume of other infectious disorders such as HIV was reduced. For instance, according to the Minnesota Department of Health, the COVID-19 pandemic resulted in disruptions of HIV testing in Minnesota, United States in the year 2020. Also, according to the Centers for Disease Control and Prevention (CDC), new HIV diagnoses reported to CDC between 2019 to 2020 registered a decline of 17%. Furthermore, it also stated a substantial decline in HIV testing from 2019 to 2020.

In addition, access to clinical services and non-essential laboratory testing for diseases such as dengue, Lyme disease, and others also impacted during the pandemic. This was mainly because the testing laboratories worldwide were preoccupied with COVID-19 testing in the initial phase of the outbreak. For instance, Boston Medical Center published a press release in December 2020. According to this press release, new research from Boston Medical Center reported that decreased in-person hospital visits in the COVID-19 pandemic resulted in a decline in hospital-wide Hepatitis C (HCV) testing by 50%. Furthermore, the research also reported a decrease in new HCV diagnoses by more than 60%. Hence, the worldwide decline in ELISA testing during the pandemic lead to a decline in the demand for ELISA analyzers.

The major factor that leads to the growth of the studied market includes the widespread prevalence of infectious diseases and cancer. Furthermore, other factors such as the rise in demand for automated and portable ELISA systems also drive the growth of the market.

The surge in the prevalence of infectious diseases leads to a rise in demand for ELISA analyzers. For instance, according to an estimate by the World Health Organization (WHO), an estimated 38.4 million people were living with HIV at the end of 2021. Similarly, as of August 2022, the WHO Pan American Health Organization (PAHO) reported 2,141,240 dengue cases in the Americas. Thus, the surge in infectious disease led to a surge in ELSIA testing which in turn led to a surge in demand for ELISA analyzers thereby driving the growth of the market.

Furthermore, ELISA is employed to quantify antibody titers which are used for the evaluation of immunogenicity during vaccine development. Hence, the rise in vaccine development activities across the globe leads to a surge in demand for ELISA analyzers thereby driving the growth of the market. For instance, according to a review by the World Health Organization (WHO), in 2021 there were 112 bacterial vaccine candidates present in the clinical stage of development. Similarly, there were 109 bacterial vaccine candidates present in the preclinical stage of development.

In addition, pharmaceutical companies such as GSK plc. and Sanofi have a substantial number of vaccine candidates in the pipeline. For instance, Sanofi has 10 vaccine candidates in its pipeline according to the latest updates at the Q2 2022 results meeting, which was held in July 2022. Hence, the surge in vaccine developmental activities leads to a rise in demand for ELISA analyzers thereby driving the growth of the market. Howerver, lack of skilled professionals & low detection limit of existing technology is expected to hinder the market growth during the study period.

ELISA Analyzers Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)